|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: ZHX2 |
Gene summary for ZHX2 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | ZHX2 | Gene ID | 22882 |
| Gene name | zinc fingers and homeoboxes 2 | |
| Gene Alias | AFR1 | |
| Cytomap | 8q24.13 | |
| Gene Type | protein-coding | GO ID | GO:0000122 | UniProtAcc | Q9Y6X8 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 22882 | ZHX2 | CCI_1 | Human | Cervix | CC | 7.07e-07 | 7.57e-01 | 0.528 |
| 22882 | ZHX2 | CCI_2 | Human | Cervix | CC | 5.95e-19 | 1.38e+00 | 0.5249 |
| 22882 | ZHX2 | CCI_3 | Human | Cervix | CC | 4.58e-13 | 8.37e-01 | 0.516 |
| 22882 | ZHX2 | AEH-subject1 | Human | Endometrium | AEH | 5.11e-16 | 4.65e-01 | -0.3059 |
| 22882 | ZHX2 | AEH-subject2 | Human | Endometrium | AEH | 1.82e-05 | 2.90e-01 | -0.2525 |
| 22882 | ZHX2 | AEH-subject3 | Human | Endometrium | AEH | 3.06e-09 | 3.96e-01 | -0.2576 |
| 22882 | ZHX2 | AEH-subject4 | Human | Endometrium | AEH | 2.08e-20 | 6.16e-01 | -0.2657 |
| 22882 | ZHX2 | AEH-subject5 | Human | Endometrium | AEH | 4.16e-18 | 4.93e-01 | -0.2953 |
| 22882 | ZHX2 | EEC-subject1 | Human | Endometrium | EEC | 2.58e-16 | 6.02e-01 | -0.2682 |
| 22882 | ZHX2 | EEC-subject2 | Human | Endometrium | EEC | 1.11e-09 | 3.67e-01 | -0.2607 |
| 22882 | ZHX2 | EEC-subject4 | Human | Endometrium | EEC | 3.28e-12 | 4.20e-01 | -0.2571 |
| 22882 | ZHX2 | EEC-subject5 | Human | Endometrium | EEC | 6.95e-04 | 2.48e-01 | -0.249 |
| 22882 | ZHX2 | LZE24T | Human | Esophagus | ESCC | 2.07e-10 | 2.74e-01 | 0.0596 |
| 22882 | ZHX2 | P1T-E | Human | Esophagus | ESCC | 8.22e-05 | 2.05e-01 | 0.0875 |
| 22882 | ZHX2 | P2T-E | Human | Esophagus | ESCC | 1.57e-04 | 8.03e-02 | 0.1177 |
| 22882 | ZHX2 | P4T-E | Human | Esophagus | ESCC | 4.54e-07 | 1.73e-01 | 0.1323 |
| 22882 | ZHX2 | P8T-E | Human | Esophagus | ESCC | 2.26e-06 | 1.56e-01 | 0.0889 |
| 22882 | ZHX2 | P9T-E | Human | Esophagus | ESCC | 1.54e-10 | 2.04e-01 | 0.1131 |
| 22882 | ZHX2 | P10T-E | Human | Esophagus | ESCC | 8.34e-13 | 2.28e-01 | 0.116 |
| 22882 | ZHX2 | P11T-E | Human | Esophagus | ESCC | 2.60e-02 | 1.26e-01 | 0.1426 |
| Page: 1 2 3 4 5 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Cervix |  | CC: Cervix cancer |
| HSIL_HPV: HPV-infected high-grade squamous intraepithelial lesions | ||
| N_HPV: HPV-infected normal cervix | ||
| Endometrium |  | AEH: Atypical endometrial hyperplasia |
| EEC: Endometrioid Cancer | ||
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Lung |  | AAH: Atypical adenomatous hyperplasia |
| AIS: Adenocarcinoma in situ | ||
| IAC: Invasive lung adenocarcinoma | ||
| MIA: Minimally invasive adenocarcinoma | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Prostate |  | BPH: Benign Prostatic Hyperplasia |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:00064029 | Cervix | CC | mRNA catabolic process | 56/2311 | 232/18723 | 4.81e-07 | 1.83e-05 | 56 |
| GO:00064019 | Cervix | CC | RNA catabolic process | 62/2311 | 278/18723 | 2.18e-06 | 6.56e-05 | 62 |
| GO:00467008 | Cervix | CC | heterocycle catabolic process | 80/2311 | 445/18723 | 3.23e-04 | 3.42e-03 | 80 |
| GO:00346559 | Cervix | CC | nucleobase-containing compound catabolic process | 74/2311 | 407/18723 | 3.77e-04 | 3.88e-03 | 74 |
| GO:00442709 | Cervix | CC | cellular nitrogen compound catabolic process | 79/2311 | 451/18723 | 7.80e-04 | 6.91e-03 | 79 |
| GO:00987275 | Cervix | CC | maintenance of cell number | 30/2311 | 134/18723 | 7.98e-04 | 7.00e-03 | 30 |
| GO:00198274 | Cervix | CC | stem cell population maintenance | 29/2311 | 131/18723 | 1.17e-03 | 9.47e-03 | 29 |
| GO:00194398 | Cervix | CC | aromatic compound catabolic process | 79/2311 | 467/18723 | 2.14e-03 | 1.54e-02 | 79 |
| GO:0150063 | Cervix | CC | visual system development | 63/2311 | 375/18723 | 6.58e-03 | 3.65e-02 | 63 |
| GO:19013618 | Cervix | CC | organic cyclic compound catabolic process | 80/2311 | 495/18723 | 6.77e-03 | 3.72e-02 | 80 |
| GO:0001654 | Cervix | CC | eye development | 62/2311 | 371/18723 | 7.83e-03 | 4.13e-02 | 62 |
| GO:0045665 | Cervix | CC | negative regulation of neuron differentiation | 16/2311 | 69/18723 | 8.75e-03 | 4.48e-02 | 16 |
| GO:0048880 | Cervix | CC | sensory system development | 63/2311 | 381/18723 | 9.29e-03 | 4.66e-02 | 63 |
| GO:000640210 | Endometrium | AEH | mRNA catabolic process | 59/2100 | 232/18723 | 9.51e-10 | 8.52e-08 | 59 |
| GO:000640110 | Endometrium | AEH | RNA catabolic process | 63/2100 | 278/18723 | 3.28e-08 | 1.87e-06 | 63 |
| GO:003465510 | Endometrium | AEH | nucleobase-containing compound catabolic process | 74/2100 | 407/18723 | 1.78e-05 | 3.65e-04 | 74 |
| GO:004427010 | Endometrium | AEH | cellular nitrogen compound catabolic process | 80/2100 | 451/18723 | 2.09e-05 | 4.13e-04 | 80 |
| GO:00467009 | Endometrium | AEH | heterocycle catabolic process | 79/2100 | 445/18723 | 2.27e-05 | 4.35e-04 | 79 |
| GO:00194399 | Endometrium | AEH | aromatic compound catabolic process | 80/2100 | 467/18723 | 7.21e-05 | 1.10e-03 | 80 |
| GO:19013619 | Endometrium | AEH | organic cyclic compound catabolic process | 83/2100 | 495/18723 | 1.13e-04 | 1.60e-03 | 83 |
| Page: 1 2 3 4 5 6 7 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| ZHX2 | SNV | Missense_Mutation | novel | c.1369A>T | p.Ser457Cys | p.S457C | Q9Y6X8 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-A8-A07J-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | 5-fluorouracil | CR |
| ZHX2 | SNV | Missense_Mutation | c.161C>G | p.Ser54Cys | p.S54C | Q9Y6X8 | protein_coding | tolerated(0.06) | benign(0.286) | TCGA-A8-A092-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | paclitaxel | CR | |
| ZHX2 | SNV | Missense_Mutation | c.417C>G | p.Phe139Leu | p.F139L | Q9Y6X8 | protein_coding | deleterious(0) | probably_damaging(0.994) | TCGA-A8-A092-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | paclitaxel | CR | |
| ZHX2 | SNV | Missense_Mutation | c.2020C>T | p.Arg674Cys | p.R674C | Q9Y6X8 | protein_coding | deleterious(0) | probably_damaging(0.991) | TCGA-AN-A0AK-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| ZHX2 | SNV | Missense_Mutation | c.2400G>T | p.Glu800Asp | p.E800D | Q9Y6X8 | protein_coding | tolerated(0.4) | benign(0.012) | TCGA-AN-A0AK-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| ZHX2 | SNV | Missense_Mutation | c.1216N>G | p.Lys406Glu | p.K406E | Q9Y6X8 | protein_coding | tolerated(0.05) | probably_damaging(0.994) | TCGA-AN-A0FS-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
| ZHX2 | SNV | Missense_Mutation | c.1216A>G | p.Lys406Glu | p.K406E | Q9Y6X8 | protein_coding | tolerated(0.05) | probably_damaging(0.994) | TCGA-AR-A250-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | SD | |
| ZHX2 | SNV | Missense_Mutation | c.2476N>C | p.Asp826His | p.D826H | Q9Y6X8 | protein_coding | deleterious_low_confidence(0) | probably_damaging(0.991) | TCGA-BH-A0BZ-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | doxorubicin | CR | |
| ZHX2 | SNV | Missense_Mutation | c.907N>A | p.Glu303Lys | p.E303K | Q9Y6X8 | protein_coding | deleterious(0) | probably_damaging(0.996) | TCGA-D8-A1JA-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | adriamycin | PD | |
| ZHX2 | SNV | Missense_Mutation | c.866A>C | p.Gln289Pro | p.Q289P | Q9Y6X8 | protein_coding | deleterious(0) | probably_damaging(0.996) | TCGA-D8-A1JP-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | tamoxiphen | SD |
| Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |